Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Common Equity (2016 - 2026)

Avanos Medical's Common Equity history spans 13 years, with the latest figure at $778.2 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 6.07% to $778.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $778.2 million, a 6.07% decrease, with the full-year FY2025 number at $778.2 million, down 6.07% from a year prior.
  • Common Equity hit $778.2 million in Q4 2025 for Avanos Medical, roughly flat from $778.0 million in the prior quarter.
  • Over the last five years, Common Equity for AVNS hit a ceiling of $1.7 billion in Q2 2024 and a floor of -$700.4 million in Q1 2025.
  • Historically, Common Equity has averaged $954.9 million across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 2781.02% in 2021 and later crashed 637.26% in 2025.
  • Tracing AVNS's Common Equity over 5 years: stood at $1.3 billion in 2021, then rose by 1.62% to $1.3 billion in 2022, then fell by 4.25% to $1.2 billion in 2023, then crashed by 32.99% to $828.5 million in 2024, then fell by 6.07% to $778.2 million in 2025.
  • Business Quant data shows Common Equity for AVNS at $778.2 million in Q4 2025, $778.0 million in Q3 2025, and -$101.9 million in Q2 2025.